{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T03:31:09Z","timestamp":1794022269283,"version":"4.8.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T00:00:00Z","timestamp":1733702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>People living with resistant hypertension (RH) are at high risk of adverse cardiovascular events. The British and Irish Hypertension Society has identified suspected RH as a condition for which specialist guidance may improve rates of blood pressure control and help clinicians identify those individuals who may benefit from specialist review. In this position statement we provide a practical approach for the investigation and management of adults with RH. We highlight gaps in the current evidence and identify important future research questions. Our aim is to support the delivery of high-quality and consistent care to people living with RH across the UK and Ireland.<\/jats:p>","DOI":"10.1038\/s41371-024-00983-6","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T07:19:01Z","timestamp":1733728741000},"page":"1-14","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Investigation and management of resistant hypertension: British and Irish Hypertension Society position statement"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1066-6899","authenticated-orcid":false,"given":"Luca","family":"Faconti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Partridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Maniero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8319-6744","authenticated-orcid":false,"given":"Abilash","family":"Sathyanarayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spoorthy","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Kapil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0986-0621","authenticated-orcid":false,"given":"Alfredo","family":"Petrosino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7903-390X","authenticated-orcid":false,"given":"Philip","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9688-6031","authenticated-orcid":false,"given":"Terry","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6292-997X","authenticated-orcid":false,"given":"Neil R.","family":"Poulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Heagerty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-9399","authenticated-orcid":false,"given":"Ian B.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,9]]},"reference":[{"issue":"10258","key":"983_CR1","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","volume":"396","author":"Global Burden of Disease Risk Factors Collaborators.","year":"2020","unstructured":"Global Burden of Disease Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223\u201349.","journal-title":"Lancet"},{"issue":"10064","key":"983_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0140-6736(16)31919-5","volume":"389","author":"NCD Risk Factor Collaboration.","year":"2017","unstructured":"NCD Risk Factor Collaboration. Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis of 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389(10064):37\u201355.","journal-title":"Lancet"},{"key":"983_CR3","unstructured":"British Heart Foundation. Cardiovascular Disease Statistics Factsheet UK 2024 2024 [Available from: https:\/\/www.bhf.org.uk\/-\/media\/files\/for-professionals\/research\/heart-statistics\/bhf-cvd-statistics-uk-factsheet.pdf."},{"issue":"13","key":"983_CR4","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","volume":"125","author":"SL Daugherty","year":"2012","unstructured":"Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635\u201342.","journal-title":"Circulation"},{"issue":"8","key":"983_CR5","doi-asserted-by":"publisher","first-page":"e104362","DOI":"10.1371\/journal.pone.0104362","volume":"9","author":"CY Hung","year":"2014","unstructured":"Hung CY, Wang KY, Wu TJ, Hsieh YC, Huang JL, Loh el W, et al. Resistant hypertension, patient characteristics, and risk of stroke. PLoS ONE. 2014;9(8):e104362.","journal-title":"PLoS ONE"},{"issue":"6","key":"983_CR6","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jash.2014.03.003","volume":"8","author":"MR Irvin","year":"2014","unstructured":"Irvin MR, Booth JN 3rd, Shimbo D, Lackland DT, Oparil S, et al. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014;8(6):405\u201313.","journal-title":"J Am Soc Hypertens"},{"issue":"3","key":"983_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/ki.2015.142","volume":"88","author":"JJ Sim","year":"2015","unstructured":"Sim JJ, Bhandari SK, Shi J, Reynolds K, Calhoun DA, Kalantar-Zadeh K, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int. 2015;88(3):622\u201332.","journal-title":"Kidney Int"},{"issue":"2","key":"983_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/HJH.0000000000000023","volume":"32","author":"C Tsioufis","year":"2014","unstructured":"Tsioufis C, Kasiakogias A, Kordalis A, Dimitriadis K, Thomopoulos C, Tsiachris D, et al. Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity: a 4-year prospective study. J Hypertens. 2014;32(2):415\u201322.","journal-title":"J Hypertens"},{"key":"983_CR9","unstructured":"National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Published 28 August 2019, Last updated: 21 November 2023. https:\/\/www.nice.org.uk\/guidance\/ng1362023."},{"issue":"12","key":"983_CR10","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874\u20132071.","journal-title":"J Hypertens"},{"issue":"6","key":"983_CR11","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","volume":"75","author":"T Unger","year":"2020","unstructured":"Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75(6):1334\u201357.","journal-title":"Hypertension"},{"issue":"38","key":"983_CR12","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","volume":"45","author":"JW McEvoy","year":"2024","unstructured":"McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912\u20134018.","journal-title":"Eur Heart J"},{"key":"983_CR13","first-page":"e13","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:e13\u2013115.","journal-title":"Hypertension."},{"issue":"5","key":"983_CR14","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cjca.2020.02.086","volume":"36","author":"DM Rabi","year":"2020","unstructured":"Rabi DM, McBrien KA, Sapir-Pichhadze R, Nakhla M, Ahmed SB, Dumanski SM, et al. Hypertension Canada\u2019s 2020 Comprehensive Guidelines for the prevention, diagnosis, risk assessment, and treatment of hypertension in adults and children. Can J Cardiol. 2020;36(5):596\u2013624.","journal-title":"Can J Cardiol"},{"issue":"25","key":"983_CR15","doi-asserted-by":"publisher","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","volume":"117","author":"DA Calhoun","year":"2008","unstructured":"Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117(25):e510\u201326.","journal-title":"Circulation"},{"issue":"10","key":"983_CR16","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1001\/jamainternmed.2023.3264","volume":"183","author":"J Ishigami","year":"2023","unstructured":"Ishigami J, Charleston J, Miller ER 3rd, Matsushita K, Appel LJ, et al. Effects of cuff size on the accuracy of blood pressure readings: the Cuff(SZ) randomized crossover trial. JAMA Intern Med. 2023;183(10):1061\u20138.","journal-title":"JAMA Intern Med"},{"issue":"3","key":"983_CR17","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/ajh\/hpu151","volume":"28","author":"D Achelrod","year":"2015","unstructured":"Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28(3):355\u201361.","journal-title":"Am J Hypertens"},{"issue":"2","key":"983_CR18","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1161\/HYPERTENSIONAHA.118.12191","volume":"73","author":"RM Carey","year":"2019","unstructured":"Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension. 2019;73(2):424\u201331.","journal-title":"Hypertension"},{"issue":"5","key":"983_CR19","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","volume":"57","author":"A de la Sierra","year":"2011","unstructured":"de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57(5):898\u2013902.","journal-title":"Hypertension"},{"issue":"3","key":"983_CR20","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1161\/HYPERTENSIONAHA.114.03565","volume":"64","author":"KM Diaz","year":"2014","unstructured":"Diaz KM, Booth JN 3rd, Calhoun DA, Irvin MR, Howard G, et al. Healthy lifestyle factors and risk of cardiovascular events and mortality in treatment-resistant hypertension: the Reasons for Geographic and Racial Differences in Stroke study. Hypertension. 2014;64(3):465\u201371.","journal-title":"Hypertension"},{"issue":"9","key":"983_CR21","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","volume":"124","author":"BM Egan","year":"2011","unstructured":"Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011;124(9):1046\u201358.","journal-title":"Circulation"},{"issue":"6","key":"983_CR22","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1161\/HYPERTENSIONAHA.111.170308","volume":"57","author":"SD Persell","year":"2011","unstructured":"Persell SD. Prevalence of resistant hypertension in the United States, 2003-2008. Hypertension. 2011;57(6):1076\u201380.","journal-title":"Hypertension"},{"issue":"9","key":"983_CR23","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2215\/CJN.00550113","volume":"8","author":"RM Tanner","year":"2013","unstructured":"Tanner RM, Calhoun DA, Bell EK, Bowling CB, Gutierrez OM, Irvin MR, et al. Prevalence of apparent treatment-resistant hypertension among individuals with CKD. Clin J Am Soc Nephrol. 2013;8(9):1583\u201390.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"983_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001398","volume":"3","author":"V Fontana","year":"2014","unstructured":"Fontana V, McDonough CW, Gong Y, El Rouby NM, Sa AC, Taylor KD, et al. Large-scale gene-centric analysis identifies polymorphisms for resistant hypertension. J Am Heart Assoc. 2014;3(6):e001398.","journal-title":"J Am Heart Assoc"},{"key":"983_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/578578","volume":"2013","author":"AI Lynch","year":"2013","unstructured":"Lynch AI, Irvin MR, Davis BR, Ford CE, Eckfeldt JH, Arnett DK. Genetic and adverse health outcome associations with treatment resistant hypertension in GenHAT. Int J Hypertens. 2013;2013:578578.","journal-title":"Int J Hypertens"},{"issue":"2","key":"983_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.gene.2012.12.059","volume":"515","author":"GH Oliveira-Paula","year":"2013","unstructured":"Oliveira-Paula GH, Lacchini R, Coeli-Lacchini FB, Junior HM, Tanus-Santos JE. Inducible nitric oxide synthase haplotype associated with hypertension and responsiveness to antihypertensive drug therapy. Gene. 2013;515(2):391\u20135.","journal-title":"Gene"},{"issue":"5","key":"983_CR27","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.semnephrol.2014.08.007","volume":"34","author":"EK Judd","year":"2014","unstructured":"Judd EK, Calhoun DA, Warnock DG. Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels. Semin Nephrol. 2014;34(5):532\u20139.","journal-title":"Semin Nephrol"},{"issue":"6","key":"983_CR28","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.116.08729","volume":"69","author":"P Gupta","year":"2017","unstructured":"Gupta P, Patel P, Strauch B, Lai FY, Akbarov A, Maresova V, et al. Risk factors for nonadherence to antihypertensive treatment. Hypertension. 2017;69(6):1113\u201320.","journal-title":"Hypertension"},{"issue":"2","key":"983_CR29","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/HYPERTENSIONAHA.120.15781","volume":"77","author":"G Parati","year":"2021","unstructured":"Parati G, Kjeldsen S, Coca A, Cushman WC, Wang J. Adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension. 2021;77(2):692\u2013705.","journal-title":"Hypertension"},{"key":"983_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2021.106467","volume":"146","author":"S Pinho","year":"2021","unstructured":"Pinho S, Cruz M, Ferreira F, Ramalho A, Sampaio R. Improving medication adherence in hypertensive patients: a scoping review. Prev Med. 2021;146:106467.","journal-title":"Prev Med"},{"issue":"11","key":"983_CR31","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/heartjnl-2013-305063","volume":"100","author":"M Tomaszewski","year":"2014","unstructured":"Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS\/MS) urine analysis. Heart. 2014;100(11):855\u201361.","journal-title":"Heart"},{"issue":"697","key":"983_CR32","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.3399\/bjgp20X710381","volume":"70","author":"JA Hodgkinson","year":"2020","unstructured":"Hodgkinson JA, Lee MM, Milner S, Bradburn P, Stevens R, Hobbs FR, et al. Accuracy of blood-pressure monitors owned by patients with hypertension (ACCU-RATE study): a cross-sectional, observational study in central England. Br J Gen Pract. 2020;70(697):e548\u201354.","journal-title":"Br J Gen Pract"},{"issue":"11","key":"983_CR33","doi-asserted-by":"publisher","first-page":"e012429","DOI":"10.1136\/bmjopen-2016-012429","volume":"6","author":"G Irving","year":"2016","unstructured":"Irving G, Holden J, Stevens R, McManus RJ. Which cuff should I use? Indirect blood pressure measurement for the diagnosis of hypertension in patients with obesity: a diagnostic accuracy review. BMJ Open. 2016;6(11):e012429.","journal-title":"BMJ Open"},{"issue":"8","key":"983_CR34","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jacc.2013.10.067","volume":"63","author":"S Brinker","year":"2014","unstructured":"Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63(8):834\u20135.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"983_CR35","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/hr.2010.183","volume":"34","author":"J Ceral","year":"2011","unstructured":"Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34(1):87\u201390.","journal-title":"Hypertens Res"},{"issue":"4","key":"983_CR36","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/HJH.0b013e32835e2286","volume":"31","author":"O Jung","year":"2013","unstructured":"Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766\u201374.","journal-title":"J Hypertens"},{"issue":"12","key":"983_CR37","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1097\/HJH.0b013e3283652c61","volume":"31","author":"B Strauch","year":"2013","unstructured":"Strauch B, Petrak O, Zelinka T, Rosa J, Somloova Z, Indra T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31(12):2455\u201361.","journal-title":"J Hypertens"},{"issue":"10","key":"983_CR38","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1097\/HJH.0b013e32834a8a42","volume":"29","author":"AK Gupta","year":"2011","unstructured":"Gupta AK, Nasothimiou EG, Chang CL, Sever PS, Dahlof B, Poulter NR. Investigators A. Baseline predictors of resistant hypertension in the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT): a risk score to identify those at high-risk. J Hypertens. 2011;29(10):2004\u201313.","journal-title":"J Hypertens"},{"issue":"10","key":"983_CR39","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.mayocp.2013.06.017","volume":"88","author":"JJ Sim","year":"2013","unstructured":"Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA, et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099\u2013107.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"983_CR40","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1161\/CIRCRESAHA.116.305697","volume":"116","author":"JE Hall","year":"2015","unstructured":"Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991\u20131006.","journal-title":"Circ Res"},{"issue":"1","key":"983_CR41","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/jch.12049","volume":"15","author":"L Landsberg","year":"2013","unstructured":"Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens. 2013;15(1):14\u201333.","journal-title":"J Clin Hypertens"},{"issue":"2","key":"983_CR42","doi-asserted-by":"publisher","first-page":"368504221102782","DOI":"10.1177\/00368504221102782","volume":"105","author":"MA Ejheisheh","year":"2022","unstructured":"Ejheisheh MA, Batran A, Ayed A, Correa-Rodriguez M, Fernandez-Aparicio A, Gomez-Urquiza JL, et al. Correlation between anthropometric measurements and blood pressure in a population of Palestinian adults. Sci Prog. 2022;105(2):368504221102782.","journal-title":"Sci Prog"},{"issue":"12","key":"983_CR43","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1097\/00004872-199412000-00018","volume":"12","author":"DW Jones","year":"1994","unstructured":"Jones DW, Kim JS, Andrew ME, Kim SJ, Hong YP. Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens. 1994;12(12):1433\u20137.","journal-title":"J Hypertens"},{"issue":"2","key":"983_CR44","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10641963.2020.1836193","volume":"43","author":"GG Sagaro","year":"2021","unstructured":"Sagaro GG, Di Canio M, Amenta F. Correlation between body mass index and blood pressure in seafarers. Clin Exp Hypertens. 2021;43(2):189\u201395.","journal-title":"Clin Exp Hypertens"},{"issue":"2","key":"983_CR45","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1097\/HJH.0b013e32835b6be7","volume":"31","author":"D Shimbo","year":"2013","unstructured":"Shimbo D, Levitan EB, Booth JN 3rd, Calhoun DA, Judd SE, et al. The contributions of unhealthy lifestyle factors to apparent resistant hypertension: findings from the Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. J Hypertens. 2013;31(2):370\u20136.","journal-title":"J Hypertens"},{"issue":"7","key":"983_CR46","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.ejim.2012.04.012","volume":"23","author":"M Holecki","year":"2012","unstructured":"Holecki M, Dulawa J, Chudek J. Resistant hypertension in visceral obesity. Eur J Intern Med. 2012;23(7):643\u20138.","journal-title":"Eur J Intern Med"},{"key":"983_CR47","unstructured":"Jehan S, Zizi F, Pandi-Perumal SR, Wall S, Auguste E, Myers AK, et al. Obstructive sleep apnea and obesity: implications for public health. Sleep Med Disord 2017;1(4):00019."},{"issue":"3","key":"983_CR48","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/2047487319879786","volume":"27","author":"C Noone","year":"2020","unstructured":"Noone C, Leahy J, Morrissey EC, Newell J, Newell M, Dwyer CP, et al. Comparative efficacy of exercise and anti-hypertensive pharmacological interventions in reducing blood pressure in people with hypertension: a network meta-analysis. Eur J Prev Cardiol. 2020;27(3):247\u201355.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"983_CR49","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.pcad.2018.07.014","volume":"61","author":"DL Swift","year":"2018","unstructured":"Swift DL, McGee JE, Earnest CP, Carlisle E, Nygard M, Johannsen NM. The effects of exercise and physical activity on weight loss and maintenance. Prog Cardiovasc Dis. 2018;61(2):206\u201313.","journal-title":"Prog Cardiovasc Dis"},{"issue":"2","key":"983_CR50","volume":"2","author":"T Semlitsch","year":"2021","unstructured":"Semlitsch T, Krenn C, Jeitler K, Berghold A, Horvath K, Siebenhofer A. Long-term effects of weight-reducing diets in people with hypertension. Cochrane Database Syst Rev. 2021;2(2):CD008274.","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"983_CR51","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000445504","volume":"9","author":"L Gilardini","year":"2016","unstructured":"Gilardini L, Redaelli G, Croci M, Conti A, Pasqualinotto L, Invitti C. Effect of a modest weight loss in normalizing blood pressure in obese subjects on antihypertensive drugs. Obes Facts. 2016;9(4):251\u20138.","journal-title":"Obes Facts"},{"issue":"8","key":"983_CR52","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11906-020-01055-z","volume":"22","author":"CA Schiavon","year":"2020","unstructured":"Schiavon CA, Pio-Abreu A, Drager LF. Bariatric surgery for resistant hypertension: working in progress! Curr Hypertens Rep. 2020;22(8):55.","journal-title":"Curr Hypertens Rep"},{"issue":"1888","key":"983_CR53","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2022.0205","volume":"378","author":"S Farooqi","year":"2023","unstructured":"Farooqi S. Obesity and thinness: insights from genetics. Philos Trans R Soc Lond B Biol Sci. 2023;378(1888):20220205.","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"11","key":"983_CR54","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989\u20131002.","journal-title":"N Engl J Med"},{"issue":"24","key":"983_CR55","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221\u201332.","journal-title":"N Engl J Med"},{"issue":"3","key":"983_CR56","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205\u201316.","journal-title":"N Engl J Med"},{"key":"983_CR57","unstructured":"National Institute for Health and Care Excellence. Obesity: identification,assessment and management. NICE Clinical Guideline [CG189]. Updated 2023. https:\/\/www.nice.org.uk\/guidance\/cg1892023."},{"key":"983_CR58","doi-asserted-by":"publisher","first-page":"f1325","DOI":"10.1136\/bmj.f1325","volume":"346","author":"FJ He","year":"2013","unstructured":"He FJ, Li J, Macgregor GA. Effect of longer term modest salt reduction on blood pressure: cochrane systematic review and meta-analysis of randomised trials. BMJ. 2013;346:f1325.","journal-title":"BMJ"},{"issue":"2","key":"983_CR59","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1161\/HYPERTENSIONAHA.107.100701","volume":"51","author":"E Pimenta","year":"2008","unstructured":"Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008;51(2):339\u201344.","journal-title":"Hypertension"},{"issue":"4","key":"983_CR60","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1378\/chest.12-0802","volume":"143","author":"E Pimenta","year":"2013","unstructured":"Pimenta E, Stowasser M, Gordon RD, Harding SM, Batlouni M, Zhang B, et al. Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest. 2013;143(4):978\u201383.","journal-title":"Chest"},{"issue":"1","key":"983_CR61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1056\/NEJM200101043440101","volume":"344","author":"FM Sacks","year":"2001","unstructured":"Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med. 2001;344(1):3\u201310.","journal-title":"N Engl J Med"},{"issue":"3","key":"983_CR62","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1161\/HYPERTENSIONAHA.123.17959","volume":"81","author":"MA Bailey","year":"2024","unstructured":"Bailey MA, Dhaun N. Salt sensitivity: causes, consequences, and recent advances. Hypertension. 2024;81(3):476\u201389.","journal-title":"Hypertension"},{"issue":"3","key":"983_CR63","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","volume":"54","author":"E Pimenta","year":"2009","unstructured":"Pimenta E, Gaddam KK, Oparil S, Aban I, Husain S, Dell\u2019Italia LJ, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension. 2009;54(3):475\u201381.","journal-title":"Hypertension"},{"issue":"11","key":"983_CR64","doi-asserted-by":"publisher","first-page":"e149","DOI":"10.1161\/HYPERTENSIONAHA.124.23382","volume":"81","author":"J Song","year":"2024","unstructured":"Song J, Chen L, Xiong H, Ma Y, Pombo-Rodrigues S, MacGregor GA, et al. Blood pressure-lowering medications, sodium reduction, and blood pressure. Hypertension. 2024;81(11):e149\u201360.","journal-title":"Hypertension"},{"issue":"12","key":"983_CR65","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1681\/ASN.2013030285","volume":"24","author":"EJ McMahon","year":"2013","unstructured":"McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, et al. A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol. 2013;24(12):2096\u2013103.","journal-title":"J Am Soc Nephrol"},{"key":"983_CR66","doi-asserted-by":"publisher","first-page":"f6954","DOI":"10.1136\/bmj.f6954","volume":"347","author":"J George","year":"2013","unstructured":"George J, Majeed W, Mackenzie IS, Macdonald TM, Wei L. Association between cardiovascular events and sodium-containing effervescent, dispersible, and soluble drugs: nested case-control study. BMJ. 2013;347:f6954.","journal-title":"BMJ"},{"issue":"7","key":"983_CR67","doi-asserted-by":"publisher","first-page":"e0180634","DOI":"10.1371\/journal.pone.0180634","volume":"12","author":"G Perrin","year":"2017","unstructured":"Perrin G, Korb-Savoldelli V, Karras A, Danchin N, Durieux P, Sabatier B. Cardiovascular risk associated with high sodium-containing drugs: a systematic review. PLoS ONE. 2017;12(7):e0180634.","journal-title":"PLoS ONE"},{"issue":"12","key":"983_CR68","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1056\/NEJMoa2105675","volume":"385","author":"B Neal","year":"2021","unstructured":"Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of salt substitution on cardiovascular events and death. N Engl J Med. 2021;385(12):1067\u201377.","journal-title":"N Engl J Med"},{"issue":"12","key":"983_CR69","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015719","volume":"9","author":"T Filippini","year":"2020","unstructured":"Filippini T, Naska A, Kasdagli MI, Torres D, Lopes C, Carvalho C, et al. Potassium intake and blood pressure: a dose-response meta-analysis of randomized controlled trials. J Am Heart Assoc. 2020;9(12):e015719.","journal-title":"J Am Heart Assoc"},{"issue":"7","key":"983_CR70","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1056\/NEJMoa1311889","volume":"371","author":"M O\u2019Donnell","year":"2014","unstructured":"O\u2019Donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L, et al. Urinary sodium and potassium excretion, mortality, and cardiovascular events. N Engl J Med. 2014;371(7):612\u201323.","journal-title":"N Engl J Med"},{"issue":"16","key":"983_CR71","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJM199704173361601","volume":"336","author":"LJ Appel","year":"1997","unstructured":"Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117\u201324.","journal-title":"N Engl J Med"},{"issue":"7","key":"983_CR72","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/HJH.0000000000003151","volume":"40","author":"PJ Smith","year":"2022","unstructured":"Smith PJ, Sherwood A, Hinderliter AL, Mabe S, Watkins LL, Craighead L, et al. Lifestyle modification and cognitive function among individuals with resistant hypertension: cognitive outcomes from the TRIUMPH trial. J Hypertens. 2022;40(7):1359\u201368.","journal-title":"J Hypertens"},{"issue":"7 Suppl","key":"983_CR73","doi-asserted-by":"publisher","first-page":"III6","DOI":"10.1002\/clc.4960221503","volume":"22","author":"FM Sacks","year":"1999","unstructured":"Sacks FM, Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, et al. A dietary approach to prevent hypertension: a review of the Dietary Approaches to Stop Hypertension (DASH) Study. Clin Cardiol. 1999;22(7 Suppl):III6\u201310.","journal-title":"Clin Cardiol"},{"issue":"6","key":"983_CR74","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/1747493016641961","volume":"11","author":"C Crump","year":"2016","unstructured":"Crump C, Sundquist J, Winkleby MA, Sundquist K. Interactive effects of physical fitness and body mass index on risk of stroke: a national cohort study. Int J Stroke. 2016;11(6):683\u201394.","journal-title":"Int J Stroke"},{"issue":"14","key":"983_CR75","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1136\/bjsports-2018-100359","volume":"53","author":"LS Pescatello","year":"2019","unstructured":"Pescatello LS. Exercise measures up to medication as antihypertensive therapy: its value has long been underestimated. Br J Sports Med. 2019;53(14):849\u201352.","journal-title":"Br J Sports Med"},{"issue":"3","key":"983_CR76","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/HYPERTENSIONAHA.112.197780","volume":"60","author":"F Dimeo","year":"2012","unstructured":"Dimeo F, Pagonas N, Seibert F, Arndt R, Zidek W, Westhoff TH. Aerobic exercise reduces blood pressure in resistant hypertension. Hypertension. 2012;60(3):653\u20138.","journal-title":"Hypertension"},{"issue":"11","key":"983_CR77","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1001\/jamacardio.2021.2735","volume":"6","author":"S Lopes","year":"2021","unstructured":"Lopes S, Mesquita-Bastos J, Garcia C, Bertoquini S, Ribau V, Teixeira M, et al. Effect of exercise training on ambulatory blood pressure among patients with resistant hypertension: a randomized clinical trial. JAMA Cardiol. 2021;6(11):1317\u201323.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"983_CR78","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1038\/s41440-023-01229-7","volume":"46","author":"S Lopes","year":"2023","unstructured":"Lopes S, Mesquita-Bastos J, Garcia C, Leitao C, Ribau V, Teixeira M, et al. Aerobic exercise improves central blood pressure and blood pressure variability among patients with resistant hypertension: results of the EnRicH trial. Hypertens Res. 2023;46(6):1547\u201357.","journal-title":"Hypertens Res"},{"issue":"3","key":"983_CR79","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1253\/circj.CJ-16-0870","volume":"81","author":"LG Cruz","year":"2017","unstructured":"Cruz LG, Bocchi EA, Grassi G, Guimaraes GV. Neurohumoral and endothelial responses to heated water-based exercise in resistant hypertensive patients. Circ J. 2017;81(3):339\u201345.","journal-title":"Circ J"},{"issue":"2","key":"983_CR80","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ijcard.2014.01.100","volume":"172","author":"GV Guimaraes","year":"2014","unstructured":"Guimaraes GV, de Barros Cruz LG, Fernandes-Silva MM, Dorea EL, Bocchi EA. Heated water-based exercise training reduces 24-hour ambulatory blood pressure levels in resistant hypertensive patients: a randomized controlled trial (HEx trial). Int J Cardiol. 2014;172(2):434\u201341.","journal-title":"Int J Cardiol"},{"key":"983_CR81","doi-asserted-by":"crossref","unstructured":"Carvalho CJ, Marins JCB, Lade CG, Castilho PR, Reis HHT, Amorim PRS, et al. Aerobic and resistance exercise in patients with resistant hypertension. Revista Brasileira de Medicina do Esporte. 2019;25(2):107\u201311.","DOI":"10.1590\/1517-869220192502175333"},{"key":"983_CR82","doi-asserted-by":"crossref","unstructured":"Saco-Ledo G, Valenzuela PL, Ruilope LM, Lucia A. Physical exercise in resistant hypertension: a systematic review and meta-analysis of randomized controlled trials. Front Cardiovasc Med. 2022;9:893811.","DOI":"10.3389\/fcvm.2022.893811"},{"issue":"6","key":"983_CR83","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1017\/S1463423618000154","volume":"19","author":"PJ Kruk","year":"2018","unstructured":"Kruk PJ, Nowicki M. Effect of the physical activity program on the treatment of resistant hypertension in primary care. Prim Health Care Res Dev. 2018;19(6):575\u201383.","journal-title":"Prim Health Care Res Dev"},{"issue":"3","key":"983_CR84","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1371\/journal.pmed.0050052","volume":"5","author":"L Chen","year":"2008","unstructured":"Chen L, Smith GD, Harbord RM, Lewis SJ. Alcohol intake and blood pressure: a systematic review implementing a Mendelian randomization approach. PLoS Med. 2008;5(3):e52.","journal-title":"PLoS Med"},{"issue":"2","key":"983_CR85","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1016\/S2468-2667(17)30003-8","volume":"2","author":"M Roerecke","year":"2017","unstructured":"Roerecke M, Kaczorowski J, Tobe SW, Gmel G, Hasan OSM, Rehm J. The effect of a reduction in alcohol consumption on blood pressure: a systematic review and meta-analysis. Lancet Public Health. 2017;2(2):e108\u2013e20.","journal-title":"Lancet Public Health"},{"key":"983_CR86","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211020892","volume":"9","author":"AF Moura","year":"2021","unstructured":"Moura AF, Moura-Neto JA, Rodrigues CIS, Miranda MO, Carvalho TC, Paschoalin Carvalho NP, et al. Resistant hypertension: prevalence and profile of patients followed in a university ambulatory. SAGE Open Med. 2021;9:20503121211020892.","journal-title":"SAGE Open Med"},{"issue":"6","key":"983_CR87","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.euroneuro.2012.06.011","volume":"23","author":"E Mick","year":"2013","unstructured":"Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol. 2013;23(6):534\u201341.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"2","key":"983_CR88","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1001\/jamapsychiatry.2023.4294","volume":"81","author":"L Zhang","year":"2024","unstructured":"Zhang L, Li L, Andell P, Garcia-Argibay M, Quinn PD, D\u2019Onofrio BM, et al. Attention-deficit\/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiatry. 2024;81(2):178\u201387.","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"983_CR89","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1524-6175.2003.00514.x","volume":"5","author":"T Morgan","year":"2003","unstructured":"Morgan T, Anderson A. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J Clin Hypertens. 2003;5(1):53\u20137.","journal-title":"J Clin Hypertens"},{"issue":"4","key":"983_CR90","first-page":"257","volume":"10","author":"AG Johnson","year":"1996","unstructured":"Johnson AG, Nguyen TV, Owe-Young R, Williamson DJ, Day RO. Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. J Hum Hypertens. 1996;10(4):257\u201361.","journal-title":"J Hum Hypertens"},{"issue":"1","key":"983_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ki.1987.164","volume":"32","author":"C Patrono","year":"1987","unstructured":"Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int. 1987;32(1):1\u201312.","journal-title":"Kidney Int"},{"issue":"3","key":"983_CR92","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2188\/jea.JE2007413","volume":"18","author":"C Ishiguro","year":"2008","unstructured":"Ishiguro C, Fujita T, Omori T, Fujii Y, Mayama T, Sato T. Assessing the effects of non-steroidal anti-inflammatory drugs on antihypertensive drug therapy using post-marketing surveillance database. J Epidemiol. 2008;18(3):119\u201324.","journal-title":"J Epidemiol"},{"issue":"4","key":"983_CR93","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archinte.1993.00410040045007","volume":"153","author":"PopeJE Anderson","year":"1993","unstructured":"Anderson PopeJE, Felson JJ. DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med. 1993;153(4):477\u201384.","journal-title":"Arch Intern Med"},{"key":"983_CR94","doi-asserted-by":"crossref","unstructured":"Jalal A, Ahmad S, Shah AT, Hussain T, Nawaz HA, Imran S. Preparation of celecoxib loaded bioactive glass chitosan composite hydrogels: a simple approach for therapeutic delivery of NSAIDs. Biomed Mater. 2024;19(3):035031.","DOI":"10.1088\/1748-605X\/ad3706"},{"issue":"26","key":"983_CR95","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, Yeomans ND, Solomon DH, Luscher TF, Libby P, Husni ME, et al. Cardiovascular safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26):2519\u201329.","journal-title":"N Engl J Med"},{"key":"983_CR96","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0002-9149(02)02661-9","volume":"90","author":"A Whelton","year":"2002","unstructured":"Whelton A, White WB, Bello AE, Puma JA, Fort JG. Investigators S-V Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol. 2002;90:959\u201363.","journal-title":"Am J Cardiol"},{"issue":"1","key":"983_CR97","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/rheumatology\/keaa209","volume":"60","author":"RE Costello","year":"2021","unstructured":"Costello RE, Yimer BB, Roads P, Jani M, Dixon WG. Glucocorticoid use is associated with an increased risk of hypertension. Rheumatology. 2021;60(1):132\u20139.","journal-title":"Rheumatology"},{"issue":"5","key":"983_CR98","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11906-021-01147-4","volume":"23","author":"M Gunaratne","year":"2021","unstructured":"Gunaratne M, Thorsteinsdottir B, Garovic VD. Combined oral contraceptive Pill-Induced hypertension and hypertensive disorders of pregnancy: shared mechanisms and clinical similarities. Curr Hypertens Rep. 2021;23(5):29.","journal-title":"Curr Hypertens Rep"},{"issue":"3","key":"983_CR99","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1210\/jcem-49-3-346","volume":"49","author":"BR Carr","year":"1979","unstructured":"Carr BR, Parker CR Jr, Madden JD, MacDonald PC, Porter JC. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment. J Clin Endocrinol Metab. 1979;49(3):346\u20139.","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"983_CR100","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1161\/HYPERTENSIONAHA.122.20018","volume":"80","author":"NA Cameron","year":"2023","unstructured":"Cameron NA, Blyler CA, Bello NA. Oral contraceptive pills and hypertension: a review of current evidence and recommendations. Hypertension. 2023;80(5):924\u201335.","journal-title":"Hypertension"},{"issue":"10","key":"983_CR101","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1177\/2047487318774847","volume":"25","author":"M Glisic","year":"2018","unstructured":"Glisic M, Shahzad S, Tsoli S, Chadni M, Asllanaj E, Rojas LZ, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis. Eur J Prev Cardiol. 2018;25(10):1042\u201352.","journal-title":"Eur J Prev Cardiol"},{"issue":"11","key":"983_CR102","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1097\/GME.0000000000001868","volume":"28","author":"J Mehta","year":"2021","unstructured":"Mehta J, Manson JE. Menopausal hormone therapy and hypertension: minimizing risk. Menopause. 2021;28(11):1201\u20132.","journal-title":"Menopause"},{"issue":"3","key":"983_CR103","first-page":"536","volume":"94","author":"JF Reckelhoff","year":"2019","unstructured":"Reckelhoff JF. Androgens and blood pressure control: sex differences and mechanisms. Mayo Clin Proc. 2019;94(3):536\u201343.","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"983_CR104","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/HYPERTENSIONAHA.120.16839","volume":"77","author":"K Banks","year":"2021","unstructured":"Banks K, Kyinn M, Leemaqz SY, Sarkodie E, Goldstein D, Irwig MS. Blood pressure effects of gender-affirming hormone therapy in transgender and gender-diverse adults. Hypertension. 2021;77(6):2066\u201374.","journal-title":"Hypertension"},{"issue":"1","key":"983_CR105","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41440-022-01067-z","volume":"46","author":"FJ Martinez-Martin","year":"2023","unstructured":"Martinez-Martin FJ, Kuzior A, Hernandez-Lazaro A, de Leon-Durango RJ, Rios-Gomez C, Santana-Ojeda B, et al. Incidence of hypertension in young transgender people after a 5-year follow-up: association with gender-affirming hormonal therapy. Hypertens Res. 2023;46(1):219\u201325.","journal-title":"Hypertens Res"},{"issue":"2","key":"983_CR106","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/HJH.0000000000001546","volume":"36","author":"JJ Rasmussen","year":"2018","unstructured":"Rasmussen JJ, Schou M, Madsen PL, Selmer C, Johansen ML, Hovind P, et al. Increased blood pressure and aortic stiffness among abusers of anabolic androgenic steroids: potential effect of suppressed natriuretic peptides in plasma? J Hypertens. 2018;36(2):277\u201385.","journal-title":"J Hypertens"},{"issue":"12","key":"983_CR107","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1097\/HJH.0000000000001805","volume":"36","author":"P Krishnamoorthy","year":"2018","unstructured":"Krishnamoorthy P, Gopalakrishnan A, Mittal V, Kalla A, Slipczuk L, Rangaswami J, et al. Gaisbock syndrome (polycythemia and hypertension) revisited: results from the national inpatient sample database. J Hypertens. 2018;36(12):2420\u20134.","journal-title":"J Hypertens"},{"issue":"4","key":"983_CR108","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/01.HYP.32.4.724","volume":"32","author":"Z Ni","year":"1998","unstructured":"Ni Z, Wang XQ, Vaziri ND. Nitric oxide metabolism in erythropoietin-induced hypertension: effect of calcium channel blockade. Hypertension. 1998;32(4):724\u20139.","journal-title":"Hypertension"},{"issue":"2","key":"983_CR109","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/cncr.28972","volume":"121","author":"OP Hamnvik","year":"2015","unstructured":"Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer. 2015;121(2):311\u20139.","journal-title":"Cancer"},{"issue":"4","key":"983_CR110","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/1120009X.2021.1947022","volume":"34","author":"G Yin","year":"2022","unstructured":"Yin G, Zhao L. Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II\/III randomized controlled trials. J Chemother. 2022;34(4):221\u201334.","journal-title":"J Chemother"},{"issue":"8","key":"983_CR111","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00228-010-0815-4","volume":"66","author":"MM An","year":"2010","unstructured":"An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, et al. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol. 2010;66(8):813\u201321.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"983_CR112","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/ckj\/sfaa174","volume":"14","author":"AG Ptinopoulou","year":"2021","unstructured":"Ptinopoulou AG, Sprangers B. Tyrosine kinase inhibitor-induced hypertension-marker of anti-tumour treatment efficacy or cardiovascular risk factor? Clin Kidney J. 2021;14(1):14\u20137.","journal-title":"Clin Kidney J"},{"key":"983_CR113","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1097\/01.hjh.0000748668.13052.17","volume":"39","author":"T Kvapil","year":"2021","unstructured":"Kvapil T, Vaclavik J, Benesova K, Jarkovsky J, Kocianova E, Kamasova M, et al. Prevalence of secondary hypertension in patients with resistant arterial hypertension. J Hypertens. 2021;39:e357.","journal-title":"J Hypertens"},{"issue":"1","key":"983_CR114","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41371-023-00882-2","volume":"38","author":"P Lewis","year":"2024","unstructured":"Lewis P, George J, Kapil V, Poulter NR, Partridge S, Goodman J, et al. Adult hypertension referral pathway and therapeutic management: British and Irish Hypertension Society position statement. J Hum Hypertens. 2024;38(1):3\u20137.","journal-title":"J Hum Hypertens"},{"issue":"27","key":"983_CR115","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa2110730","volume":"385","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Sinha AD, Cramer AE, Balmes-Fenwick M, Dickinson JH, Ouyang F, et al. Chlorthalidone for hypertension in advanced chronic kidney disease. N Engl J Med. 2021;385(27):2507\u201319.","journal-title":"N Engl J Med"},{"issue":"3","key":"983_CR116","doi-asserted-by":"publisher","first-page":"PL45","DOI":"10.1016\/S0024-3205(98)00265-3","volume":"63","author":"TL Goodfriend","year":"1998","unstructured":"Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63(3):PL45\u201350.","journal-title":"Life Sci"},{"issue":"11","key":"983_CR117","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/S0895-7061(02)03000-5","volume":"15","author":"G Leonetti","year":"2002","unstructured":"Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B, Zanchetti A, et al. Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens. 2002;15(11):932\u201340.","journal-title":"Am J Hypertens"},{"issue":"26","key":"983_CR118","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1056\/NEJMoa2212270","volume":"387","author":"A Ishani","year":"2022","unstructured":"Ishani A, Cushman WC, Leatherman SM, Lew RA, Woods P, Glassman PA, et al. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. N Engl J Med. 2022;387(26):2401\u201310.","journal-title":"N Engl J Med"},{"issue":"9","key":"983_CR119","doi-asserted-by":"publisher","first-page":"e2123365","DOI":"10.1001\/jamanetworkopen.2021.23365","volume":"4","author":"C Edwards","year":"2021","unstructured":"Edwards C, Hundemer GL, Petrcich W, Canney M, Knoll G, Burns K, et al. Comparison of clinical outcomes and safety associated with chlorthalidone vs hydrochlorothiazide in older adults with varying levels of kidney function. JAMA Netw Open. 2021;4(9):e2123365.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"983_CR120","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1001\/jamainternmed.2019.7454","volume":"180","author":"G Hripcsak","year":"2020","unstructured":"Hripcsak G, Suchard MA, Shea S, Chen R, You SC, Pratt N, et al. Comparison of cardiovascular and safety outcomes of chlorthalidone vs hydrochlorothiazide to treat hypertension. JAMA Intern Med. 2020;180(4):542\u201351.","journal-title":"JAMA Intern Med"},{"key":"983_CR121","unstructured":"Medicines and Healthcare products Regulatory Agency. Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use. Published 14 November 2018. https:\/\/www.gov.uk\/drug-safety-update\/hydrochlorothiazide-risk-of-non-melanoma-skin-cancer-particularly2018."},{"issue":"4","key":"983_CR122","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/s41371-019-0190-2","volume":"33","author":"L Faconti","year":"2019","unstructured":"Faconti L, Ferro A, Webb AJ, Cruickshank JK, Chowienczyk PJ. British, Irish Hypertension S. Hydrochlorothiazide and the risk of skin cancer. A scientific statement of the British and Irish Hypertension Society. J Hum Hypertens. 2019;33(4):257\u20138.","journal-title":"J Hum Hypertens"},{"issue":"10008","key":"983_CR123","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386(10008):2059\u201368.","journal-title":"Lancet"},{"issue":"4","key":"983_CR124","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49(4):839\u201345.","journal-title":"Hypertension"},{"issue":"11","key":"983_CR125","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1001\/archinte.168.11.1159","volume":"168","author":"KK Gaddam","year":"2008","unstructured":"Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, Calhoun DA. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159\u201364.","journal-title":"Arch Intern Med"},{"issue":"2","key":"983_CR126","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1161\/HYPERTENSIONAHA.115.06526","volume":"67","author":"J Rosa","year":"2016","unstructured":"Rosa J, Widimsky P, Waldauf P, Lambert L, Zelinka T, Taborsky M, et al. Role of adding spironolactone and renal denervation in true resistant hypertension: one-year outcomes of randomized PRAGUE-15 Study. Hypertension. 2016;67(2):397\u2013403.","journal-title":"Hypertension"},{"issue":"10","key":"983_CR127","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.hlc.2016.02.016","volume":"25","author":"C Wang","year":"2016","unstructured":"Wang C, Xiong B, Huang J. Efficacy and safety of spironolactone in patients with resistant hypertension: a meta-analysis of randomised controlled trials. Heart Lung Circ. 2016;25(10):1021\u201330.","journal-title":"Heart Lung Circ"},{"key":"983_CR128","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ijcard.2016.12.158","volume":"233","author":"D Zhao","year":"2017","unstructured":"Zhao D, Liu H, Dong P, Zhao J. A meta-analysis of add-on use of spironolactone in patients with resistant hypertension. Int J Cardiol. 2017;233:113\u20137.","journal-title":"Int J Cardiol"},{"issue":"6","key":"983_CR129","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","volume":"6","author":"B Williams","year":"2018","unstructured":"Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies. Lancet Diabetes Endocrinol. 2018;6(6):464\u201375.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"983_CR130","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/IBPC.S188869","volume":"12","author":"BT Enslow","year":"2019","unstructured":"Enslow BT, Stockand JD, Berman JM. Liddle\u2019s syndrome mechanisms, diagnosis and management. Integr Blood Press Control. 2019;12:13\u201322.","journal-title":"Integr Blood Press Control"},{"key":"983_CR131","doi-asserted-by":"crossref","unstructured":"Zilbermint M, Hannah-Shmouni F, Stratakis CA. Genetics of hypertension in African Americans and Others of African Descent. Int J Mol Sci. 2019;20(5):1081.","DOI":"10.3390\/ijms20051081"},{"issue":"1","key":"983_CR132","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","volume":"31","author":"G Colussi","year":"2013","unstructured":"Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31(1):3\u201315.","journal-title":"J Hypertens"},{"issue":"5","key":"983_CR133","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1046\/j.1365-2125.1999.00067.x","volume":"48","author":"M Chung","year":"1999","unstructured":"Chung M, Vashi V, Puente J, Sweeney M, Meredith P. Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol. 1999;48(5):678\u201387.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"983_CR134","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","volume":"71","author":"EM Krieger","year":"2018","unstructured":"Krieger EM, Drager LF, Giorgi DMA, Pereira AC, Barreto-Filho JAS, Nogueira AR, et al. Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT randomized study (Resistant Hypertension Optimal Treatment). Hypertension. 2018;71(4):681\u201390.","journal-title":"Hypertension"},{"key":"983_CR135","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1748-1716.1946.tb00368.x","volume":"12","author":"U Euler","year":"1946","unstructured":"Euler U. A specific sympathomimetic ergone in adrenergic nerve fibres (Sympathin) and its relations to adrenaline and nor-adrenaline. Acta Physiol Scand. 1946;12:73\u201397.","journal-title":"Acta Physiol Scand"},{"key":"983_CR136","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/00005344-200000004-00001","volume":"35","author":"M Esler","year":"2000","unstructured":"Esler M, Kaye D. Sympathetic nervous system activation in essential hypertension, cardiac failure and psychosomatic heart disease. J Cardiovasc Pharmacol. 2000;35:S1\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"983_CR137","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1161\/CIRCRESAHA.116.303604","volume":"116","author":"G Grassi","year":"2015","unstructured":"Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976\u201390.","journal-title":"Circ Res"},{"issue":"9671","key":"983_CR138","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","volume":"373","author":"H Krum","year":"2009","unstructured":"Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373(9671):1275\u201381.","journal-title":"Lancet"},{"issue":"9756","key":"983_CR139","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","volume":"376","author":"HTNI Symplicity","year":"2010","unstructured":"Symplicity HTNI, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376(9756):1903\u20139.","journal-title":"Lancet"},{"issue":"15","key":"983_CR140","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW, D\u2019Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393\u2013401.","journal-title":"N Engl J Med"},{"issue":"1","key":"983_CR141","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1136\/heartjnl-2014-307029","volume":"101","author":"MD Lobo","year":"2015","unstructured":"Lobo MD, de Belder MA, Cleveland T, Collier D, Dasgupta I, Deanfield J, et al. Joint UK societies\u2019 2014 consensus statement on renal denervation for resistant hypertension. Heart. 2015;101(1):10\u20136.","journal-title":"Heart"},{"issue":"19","key":"983_CR142","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1136\/heartjnl-2019-315098","volume":"105","author":"MD Lobo","year":"2019","unstructured":"Lobo MD, Sharp ASP, Kapil V, Davies J, de Belder MA, Cleveland T, et al. Joint UK societies\u2019 2019 consensus statement on renal denervation. Heart. 2019;105(19):1456\u201363.","journal-title":"Heart"},{"issue":"11","key":"983_CR143","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.121.057687","volume":"145","author":"DE Kandzari","year":"2022","unstructured":"Kandzari DE, Mahfoud F, Weber MA, Townsend R, Parati G, Fisher NDL, et al. Clinical trial design principles and outcomes definitions for device-based therapies for hypertension: a consensus document from the hypertension academic research consortium. Circulation. 2022;145(11):847\u201363.","journal-title":"Circulation"},{"issue":"33","key":"983_CR144","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1093\/eurheartj\/ehv192","volume":"36","author":"F Mahfoud","year":"2015","unstructured":"Mahfoud F, Bohm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J. 2015;36(33):2219\u201327.","journal-title":"Eur Heart J"},{"issue":"10293","key":"983_CR145","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","volume":"397","author":"M Azizi","year":"2021","unstructured":"Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397(10293):2476\u201386.","journal-title":"Lancet"},{"issue":"19","key":"983_CR146","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.jacc.2023.08.045","volume":"82","author":"Kandzari","year":"2023","unstructured":"Kandzari, Townsend DE, Kario RR, Mahfoud K, Weber MA F, Schmieder RE, et al. Safety and efficacy of renal denervation in patients taking antihypertensive medications. J Am Coll Cardiol. 2023;82(19):1809\u201323.","journal-title":"J Am Coll Cardiol"},{"issue":"3-4","key":"983_CR147","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000490620","volume":"6","author":"K Kario","year":"2019","unstructured":"Kario K, Rumoroso JR, Okawara Y, Perez de Prado A, Garcia Fernandez E, Kagitani H, et al. Renal sympathetic denervation in patients with resistant hypertension: a feasibility study. Pulse. 2019;6(3-4):137\u201343.","journal-title":"Pulse"},{"issue":"1","key":"983_CR148","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4244\/EIJ-D-19-00902","volume":"16","author":"RR Townsend","year":"2020","unstructured":"Townsend RR, Walton A, Hettrick DA, Hickey GL, Weil J, Sharp ASP, et al. Review and meta-analysis of renal artery damage following percutaneous renal denervation with radiofrequency renal artery ablation. EuroIntervention. 2020;16(1):89\u201396.","journal-title":"EuroIntervention"},{"issue":"10137","key":"983_CR149","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"Kandzari","year":"2018","unstructured":"Kandzari, Bohm DE, Mahfoud M, Townsend F, Weber MA RR, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391(10137):2346\u201355.","journal-title":"Lancet"},{"issue":"2","key":"983_CR150","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41440-021-00754-7","volume":"45","author":"K Kario","year":"2022","unstructured":"Kario K, Yokoi Y, Okamura K, Fujihara M, Ogoyama Y, Yamamoto E, et al. Catheter-based ultrasound renal denervation in patients with resistant hypertension: the randomized, controlled REQUIRE trial. Hypertens Res. 2022;45(2):221\u201331.","journal-title":"Hypertens Res"},{"key":"983_CR151","unstructured":"Sunman W, Brady A, Poulter N, Lewis P, Partridge S, Faconti L, Kulkarni S, et al. BIHS Statement on Renal Denervation (RDN) following publication of the NICE Interventional Procedures Guidance IPG754: Percutaneous transluminal renal sympathetic denervation for resistant hypertension https:\/\/bihs.org.uk\/wp-content\/uploads\/2023\/05\/BIHS-statement-on-NICE-IPG754-RDN-10-5-2023-002.pdf2023."},{"issue":"10367","key":"983_CR152","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/S0140-6736(22)02034-7","volume":"400","author":"MP Schlaich","year":"2022","unstructured":"Schlaich MP, Bellet M, Weber MA, Danaietash P, Bakris GL, Flack JM, et al. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400(10367):1927\u201337.","journal-title":"Lancet"},{"issue":"4","key":"983_CR153","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1161\/HYPERTENSIONAHA.119.14504","volume":"75","author":"P Verweij","year":"2020","unstructured":"Verweij P, Danaietash P, Flamion B, Menard J, Bellet M. Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension. Hypertension. 2020;75(4):956\u201365.","journal-title":"Hypertension"},{"issue":"36","key":"983_CR154","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1093\/eurheartj\/ehab499","volume":"42","author":"AM Jackson","year":"2021","unstructured":"Jackson AM, Jhund PS, Anand IS, Dungen HD, Lam CSP, Lefkowitz MP, et al. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. Eur Heart J. 2021;42(36):3741\u201352.","journal-title":"Eur Heart J"},{"issue":"8","key":"983_CR155","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.tcm.2022.05.005","volume":"33","author":"R Gupta","year":"2023","unstructured":"Gupta R, Maitz T, Egeler D, Mehta A, Nyaeme M, Hajra A, et al. SGLT2 inhibitors in hypertension: role beyond diabetes and heart failure. Trends Cardiovasc Med. 2023;33(8):479\u201386.","journal-title":"Trends Cardiovasc Med"},{"issue":"38","key":"983_CR156","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1093\/eurheartj\/ehae564","volume":"45","author":"C Kennedy","year":"2024","unstructured":"Kennedy C, Hayes P, Cicero AFG, Dobner S, Le Roux CW, McEvoy JW, et al. Semaglutide and blood pressure: an individual patient data meta-analysis. Eur Heart J. 2024;45(38):4124\u201334.","journal-title":"Eur Heart J"},{"issue":"7","key":"983_CR157","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41371-024-00922-5","volume":"38","author":"S Kulkarni","year":"2024","unstructured":"Kulkarni S, Faconti L, Partridge S, Delles C, Glover M, Lewis P, et al. Investigation and management of young-onset hypertension: British and Irish hypertension society position statement. J Hum Hypertens. 2024;38(7):544\u201354.","journal-title":"J Hum Hypertens"},{"issue":"11","key":"983_CR158","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011318","volume":"8","author":"SA Shah","year":"2019","unstructured":"Shah SA, Szeto AH, Farewell R, Shek A, Fan D, Quach KN, et al. Impact of high volume energy drink consumption on electrocardiographic and blood pressure parameters: a randomized trial. J Am Heart Assoc. 2019;8(11):e011318.","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00983-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00983-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00983-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,10]],"date-time":"2025-01-10T00:02:59Z","timestamp":1736467379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-024-00983-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":158,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["983"],"URL":"https:\/\/doi.org\/10.1038\/s41371-024-00983-6","relation":{},"ISSN":["1476-5527"],"issn-type":[{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,9]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Professor Adrian J.B. Brady has received honoraria from Daiichi-Sankyo, Amgen, Sanofi-Aventis, Bayer, MSD, and Novartis. Professor Phil Chowienczyk has an interest in Centron Diagnostics, a company that has produced technology for blood pressure measurement. Professor Jacob George has received grants and travel funding from Astra Zeneca, Novartis and Daiichi Sankyo, is on Advisory Boards for AstraZeneca, Menarini and Novartis, consulting fees from Roche and PwC and is a Principal Investigator for studies funded by AstraZeneca, Alnylam, Novartis, Esperion. Dr Pankaj Gupta has received research grants, lecture honoraria and funding for conference attendance from Sanofi-Aventis and Amgen, and consulting fees from Ionis Pharmaceuticals. Professor Anthony Heagerty has received lecture honoraria from Servier. Dr Spoorthy Kulkarni is a PhD student at the University of Cambridge funded by AstraZeneca and has attended scientific advisory boards for Viatris. Professor Terry McCormack has received lecture honoraria and\/or consultation fees from AstraZeneca, Daichi-Sankyo, and Medtronic. He is a co-investigator in the Alnylam study Kardia 3. Professor Neil R Poulter has received lecture honoraria and\/or consultation fees from several pharmaceutical companies that manufacture blood pressure lowering agents including AstraZeneca, Eva Pharma, Lri Therapharma, Napi, Pfizer, Servier and Sanofi-Aventis. Professor Ian B Wilkinson has received research grants from AstraZeneca, GSK and scientific advisory board consultation fees for Viatris, Astra Zeneca and Roche. Dr Luca Faconti, Dr Carmen Maniero, Dr Vikas Kapil, Dr Philip Lewis, Ms Michaela Nuttall, Mr Sam Olden, Dr Sarah Partridge, Dr Alfredo Petrosino, Dr Abilash Sathyanarayanan, Professor Peter Sever, Dr Wayne Sunman and Dr Helen Warren have no competing interests to declare for this manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}